JP2012502946A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502946A5 JP2012502946A5 JP2011527300A JP2011527300A JP2012502946A5 JP 2012502946 A5 JP2012502946 A5 JP 2012502946A5 JP 2011527300 A JP2011527300 A JP 2011527300A JP 2011527300 A JP2011527300 A JP 2011527300A JP 2012502946 A5 JP2012502946 A5 JP 2012502946A5
- Authority
- JP
- Japan
- Prior art keywords
- ynyloxy
- hydroxyamino
- benzamide
- amino
- oxobutan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 8
- -1 1- (1-aminocyclopropyl) -2- (hydroxyamino) -2-oxoethyl Chemical group 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 241000589291 Acinetobacter Species 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 241000588921 Enterobacteriaceae Species 0.000 claims 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 2
- 241000588653 Neisseria Species 0.000 claims 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 2
- 241000588769 Proteus <enterobacteria> Species 0.000 claims 2
- 241000607142 Salmonella Species 0.000 claims 2
- 241000607720 Serratia Species 0.000 claims 2
- 241000122973 Stenotrophomonas maltophilia Species 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 208000027096 gram-negative bacterial infections Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- MMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 claims 1
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 241001673062 Achromobacter xylosoxidans Species 0.000 claims 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241000606125 Bacteroides Species 0.000 claims 1
- 241000588807 Bordetella Species 0.000 claims 1
- 241001453380 Burkholderia Species 0.000 claims 1
- 241000589513 Burkholderia cepacia Species 0.000 claims 1
- 241000046135 Cedecea Species 0.000 claims 1
- 241000588923 Citrobacter Species 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241000588914 Enterobacter Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000589601 Francisella Species 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 241000606790 Haemophilus Species 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 241000588748 Klebsiella Species 0.000 claims 1
- 241000589248 Legionella Species 0.000 claims 1
- 208000007764 Legionnaires' Disease Diseases 0.000 claims 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 1
- 241000588621 Moraxella Species 0.000 claims 1
- 241000588771 Morganella <proteobacterium> Species 0.000 claims 1
- 108010040201 Polymyxins Proteins 0.000 claims 1
- 241000588768 Providencia Species 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 241000607768 Shigella Species 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims 1
- 241000607598 Vibrio Species 0.000 claims 1
- 241000607734 Yersinia <bacteria> Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229960000723 ampicillin Drugs 0.000 claims 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- 229960003644 aztreonam Drugs 0.000 claims 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 1
- 229960002100 cefepime Drugs 0.000 claims 1
- 229960004261 cefotaxime Drugs 0.000 claims 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 claims 1
- 229960000484 ceftazidime Drugs 0.000 claims 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims 1
- 229960004755 ceftriaxone Drugs 0.000 claims 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 229960002227 clindamycin Drugs 0.000 claims 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims 1
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960003276 erythromycin Drugs 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 229960002182 imipenem Drugs 0.000 claims 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 229960003376 levofloxacin Drugs 0.000 claims 1
- 229960002260 meropenem Drugs 0.000 claims 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims 1
- OWQGGUZHYIFZRN-RNCFNFMXSA-N n-[(2s,3r)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl]-4-but-2-ynoxy-2-fluorobenzamide Chemical compound CC#CCOC1=CC=C(C(=O)N[C@@H]([C@@H](C)N)C(=O)NO)C(F)=C1 OWQGGUZHYIFZRN-RNCFNFMXSA-N 0.000 claims 1
- 229940056360 penicillin g Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960002292 piperacillin Drugs 0.000 claims 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 claims 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 1
- 229960001225 rifampicin Drugs 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- 229930101283 tetracycline Natural products 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims 1
- 229960004659 ticarcillin Drugs 0.000 claims 1
- 229960000707 tobramycin Drugs 0.000 claims 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9766408P | 2008-09-17 | 2008-09-17 | |
| US61/097,664 | 2008-09-17 | ||
| PCT/EP2009/061905 WO2010031750A1 (en) | 2008-09-17 | 2009-09-15 | Organic compounds for applications in bacterial infections treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012502946A JP2012502946A (ja) | 2012-02-02 |
| JP2012502946A5 true JP2012502946A5 (enExample) | 2012-11-01 |
| JP5550650B2 JP5550650B2 (ja) | 2014-07-16 |
Family
ID=41397755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011527300A Expired - Fee Related JP5550650B2 (ja) | 2008-09-17 | 2009-09-15 | 細菌感染症処置に適用するための有機化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8372885B2 (enExample) |
| EP (1) | EP2340241A1 (enExample) |
| JP (1) | JP5550650B2 (enExample) |
| KR (1) | KR20110055735A (enExample) |
| CN (1) | CN102159537B (enExample) |
| AR (1) | AR074719A1 (enExample) |
| AU (1) | AU2009294710A1 (enExample) |
| CA (1) | CA2737524A1 (enExample) |
| EA (1) | EA201100505A1 (enExample) |
| MX (1) | MX2011002804A (enExample) |
| TW (1) | TW201018460A (enExample) |
| UY (1) | UY32123A (enExample) |
| WO (1) | WO2010031750A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008154642A2 (en) * | 2007-06-12 | 2008-12-18 | Achaogen, Inc. | Antibacterial agents |
| EP2334636A2 (en) | 2008-09-19 | 2011-06-22 | Pfizer Inc. | Hydroxamic acid derivatives useful as antibacterial agents |
| WO2011005355A1 (en) * | 2009-05-07 | 2011-01-13 | Achaogen, Inc. | Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria |
| JP5591494B2 (ja) * | 2009-07-14 | 2014-09-17 | 東ソ−・エフテック株式会社 | 高純度の含フッ素エチリデン−２−メチルプロパンスルフィンアミド、その製造方法及びそれを用いた光学活性含フッ素アミン誘導体の製造方法 |
| PL2512474T3 (pl) | 2009-12-16 | 2015-03-31 | Pfizer | N-przyłączone pochodne kwasu hydroksamowego użyteczne jako środki przeciwbakteryjne |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| PH12012502087A1 (en) | 2010-04-20 | 2015-04-15 | Taisho Pharmaceutical Co Ltd | Novel hydroxamic acid derivative |
| US9738604B2 (en) | 2010-09-03 | 2017-08-22 | Duke University | Ethynylbenzene derivatives |
| AP3336A (en) | 2011-03-07 | 2015-07-31 | Pfizer | Fluoro-pyridinone derivatives useful as antibacterial agents |
| SG193458A1 (en) | 2011-04-08 | 2013-10-30 | Pfizer | Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents |
| CN103717582B (zh) | 2011-04-08 | 2015-09-30 | 辉瑞大药厂 | 用作抗菌剂的异*唑衍生物 |
| JP6006609B2 (ja) * | 2011-10-19 | 2016-10-12 | 大正製薬株式会社 | 新規なヒドロキサム酸誘導体を含有する医薬 |
| JP5869311B2 (ja) * | 2011-11-21 | 2016-02-24 | 国立大学法人 名古屋工業大学 | 光学活性含フッ素β−アミノ酸誘導体及びその製造法 |
| WO2013170165A1 (en) | 2012-05-10 | 2013-11-14 | Achaogen, Inc. | Antibacterial agents |
| JP5902575B2 (ja) * | 2012-07-20 | 2016-04-13 | 国立大学法人お茶の水女子大学 | 光学活性含フッ素アミン化合物の製造方法並びに光学活性含フッ素アミン化合物 |
| CN104470940B (zh) | 2012-09-19 | 2018-10-16 | 霍夫曼-拉罗奇有限公司 | 2-氧代-2，3，4，5-四氢-1H-苯并[b][1，4]二氮杂*及其治疗癌症的用途 |
| WO2014165075A1 (en) | 2013-03-12 | 2014-10-09 | Achaogen, Inc. | Antibacterial agents |
| TR201911245T4 (tr) | 2013-03-15 | 2019-08-21 | Fujifilm Toyama Chemical Co Ltd | Yeni hidroksamik asit türevi veya bunun tuzu. |
| CA2921427A1 (en) * | 2013-08-16 | 2015-02-19 | Duke University | Substituted hydroxamic acid compounds |
| US9908851B2 (en) | 2013-08-16 | 2018-03-06 | Duke University | 2-piperidinyl substituted N,3-dihydroxybutanamides |
| US10189786B2 (en) | 2013-08-16 | 2019-01-29 | Duke University | Antibacterial compounds |
| KR20170048546A (ko) | 2014-09-12 | 2017-05-08 | 토야마 케미칼 컴퍼니 리미티드 | 신규 히드록삼산 유도체 또는 그 염을 함유하는 의약 조성물 |
| JPWO2016039432A1 (ja) | 2014-09-12 | 2017-06-22 | 富山化学工業株式会社 | 新規なヒドロキサム酸誘導体および抗菌性物質を組み合わせて使用する方法 |
| CN105669750B (zh) * | 2016-03-01 | 2018-04-03 | 中国医学科学院医药生物技术研究所 | 新型锌离子螯合剂及其制备和在抗革兰氏阴性菌感染中的应用 |
| EP3448375B1 (en) | 2016-04-25 | 2023-09-27 | Duke University | Benzoylglycine derivatives and methods of making and using same |
| WO2017223349A1 (en) | 2016-06-23 | 2017-12-28 | Achaogen, Inc. | Antibacterial agents |
| US11299455B2 (en) | 2018-07-12 | 2022-04-12 | Piramal Pharma Limited | Process for diastereoselective synthesis of vicinal diamines |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1577345A (en) | 1976-06-10 | 1980-10-22 | Eisai Co Ltd | Hydroxamic acid derivatives of use in the treatment of urolithiasis and pyelonephrosis |
| US6951884B2 (en) | 2002-06-12 | 2005-10-04 | Hoffmann-La Roche Inc. | Fluorobenzamides and uses thereof |
| SG2012000667A (en) * | 2003-01-08 | 2015-03-30 | Univ Washington | Antibacterial agents |
| CA2528231A1 (en) | 2003-06-13 | 2004-12-23 | Laboratorios S.A.L.V.A.T., S.A. | New benzamides as ppar.gamma. modulators |
| US7714168B2 (en) | 2005-10-27 | 2010-05-11 | Sumitomo Chemical Company, Limited | Amide compounds and their use |
| WO2008154642A2 (en) * | 2007-06-12 | 2008-12-18 | Achaogen, Inc. | Antibacterial agents |
-
2009
- 2009-09-11 US US12/557,654 patent/US8372885B2/en not_active Expired - Fee Related
- 2009-09-15 EA EA201100505A patent/EA201100505A1/ru unknown
- 2009-09-15 EP EP09782998A patent/EP2340241A1/en not_active Withdrawn
- 2009-09-15 MX MX2011002804A patent/MX2011002804A/es not_active Application Discontinuation
- 2009-09-15 CA CA2737524A patent/CA2737524A1/en not_active Abandoned
- 2009-09-15 AU AU2009294710A patent/AU2009294710A1/en not_active Abandoned
- 2009-09-15 WO PCT/EP2009/061905 patent/WO2010031750A1/en not_active Ceased
- 2009-09-15 CN CN200980136312.2A patent/CN102159537B/zh not_active Expired - Fee Related
- 2009-09-15 KR KR1020117008624A patent/KR20110055735A/ko not_active Withdrawn
- 2009-09-15 JP JP2011527300A patent/JP5550650B2/ja not_active Expired - Fee Related
- 2009-09-15 AR ARP090103529A patent/AR074719A1/es unknown
- 2009-09-16 TW TW098131268A patent/TW201018460A/zh unknown
- 2009-09-16 UY UY0001032123A patent/UY32123A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012502946A5 (enExample) | ||
| JP2017510580A5 (enExample) | ||
| JP2014501716A5 (enExample) | ||
| CN101951868B (zh) | 用于治疗阴道感染和致病性阴道生物被膜的组合物和方法 | |
| Falagas et al. | Old antibiotics for infections in critically ill patients | |
| JP2016535758A5 (enExample) | ||
| RU2008146815A (ru) | Фармацевтическая комбинация, включающая 3-(3-диметиламино-1-этил-2-метилпропил)фенол т нестероидный противовоспалительный препарат | |
| NZ631469A (en) | Aerosol fluoroquinolone formulations for improved pharmacokinetics | |
| JP2010513478A5 (enExample) | ||
| CA2433197A1 (en) | Gyrase inhibitors and uses thereof | |
| CY1114621T1 (el) | Συνταγοποιηση εισπνευσιμης λυσινικης αζτρεοναμης για τη θεραπευτικη αγωγη και προληψη πνευμονικων βακτηριακων μολυνσεων | |
| JP2008521827A5 (enExample) | ||
| JP2013541514A5 (enExample) | ||
| CY1111571T1 (el) | Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων | |
| JP2020537659A5 (enExample) | ||
| HRP20211762T1 (hr) | Derivati benzoksaborola za liječenje bakterijskih infekcija | |
| JP2011524850A5 (enExample) | ||
| JP2015521617A5 (enExample) | ||
| HRP20110076T1 (hr) | Farmaceutske kombinacije koje sadrže 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i paracetamol | |
| JP2017517547A5 (enExample) | ||
| HRP20150049T1 (hr) | Derivati oksazolil-metiletera kao agonisti alx-receptora | |
| JP2017513892A5 (enExample) | ||
| JP2010527960A5 (enExample) | ||
| TN2009000487A1 (en) | Triazol compounds for treating biofilm formation | |
| JP2009521417A5 (enExample) |